A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

LESSONS LEARNED. The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs). Molecular profiling of GISTs at diagnosis and up...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Rosenbaum, Evan, Kelly, Ciara, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal, Keohan, Mary L., Movva, Sujana, Condy, Mercedes, Adamson, Travis, Mcfadyen, Chloe R., Antonescu, Christina R., Hwang, Sinchun, Singer, Sam, Qin, Li‐Xuan, Tap, William D., Chi, Ping
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2019
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795162/
https://ncbi.nlm.nih.gov/pubmed/31213500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0418
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller